DE69824842D1 - Kontrastmittel, die auf angiogenese-rezeptoren zielen - Google Patents
Kontrastmittel, die auf angiogenese-rezeptoren zielenInfo
- Publication number
- DE69824842D1 DE69824842D1 DE69824842T DE69824842T DE69824842D1 DE 69824842 D1 DE69824842 D1 DE 69824842D1 DE 69824842 T DE69824842 T DE 69824842T DE 69824842 T DE69824842 T DE 69824842T DE 69824842 D1 DE69824842 D1 DE 69824842D1
- Authority
- DE
- Germany
- Prior art keywords
- contrast agent
- contrast agents
- moiety
- agents targeting
- image
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1255—Granulates, agglomerates, microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Steroid Compounds (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9708265.5A GB9708265D0 (en) | 1997-04-24 | 1997-04-24 | Contrast agents |
GB9708265 | 1997-04-24 | ||
PCT/GB1998/001197 WO1998047541A1 (en) | 1997-04-24 | 1998-04-24 | Contrast agents |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69824842D1 true DE69824842D1 (de) | 2004-08-05 |
DE69824842T2 DE69824842T2 (de) | 2005-11-17 |
Family
ID=10811256
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69837975T Expired - Lifetime DE69837975T2 (de) | 1997-04-24 | 1998-04-24 | Diagnostisches Abbildungsverfahren |
DE69824842T Expired - Lifetime DE69824842T2 (de) | 1997-04-24 | 1998-04-24 | Kontrastmittel, die auf angiogenese-rezeptoren zielen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69837975T Expired - Lifetime DE69837975T2 (de) | 1997-04-24 | 1998-04-24 | Diagnostisches Abbildungsverfahren |
Country Status (10)
Country | Link |
---|---|
US (2) | US6610269B1 (de) |
EP (2) | EP0977600B1 (de) |
JP (1) | JP4993419B2 (de) |
AT (2) | ATE270116T1 (de) |
AU (1) | AU7068798A (de) |
DE (2) | DE69837975T2 (de) |
DK (1) | DK1442751T3 (de) |
ES (2) | ES2224379T3 (de) |
GB (1) | GB9708265D0 (de) |
WO (1) | WO1998047541A1 (de) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9708265D0 (en) * | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
US6245318B1 (en) | 1997-05-27 | 2001-06-12 | Mallinckrodt Inc. | Selectively binding ultrasound contrast agents |
US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
AU5541799A (en) | 1998-03-31 | 1999-11-29 | Du Pont Pharmaceuticals Company | Pharmaceuticals for the imaging of angiogenic disorders |
US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
DE19845798A1 (de) * | 1998-09-29 | 2000-04-13 | Schering Ag | Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung |
US6652836B2 (en) | 1998-10-15 | 2003-11-25 | Fluoroprobe, Inc. | Method for viewing tumor tissue located within a body cavity |
US6299860B1 (en) | 1998-10-15 | 2001-10-09 | Fluoro Probe, Inc. | Method for viewing diseased tissue located within a body cavity |
US6284223B1 (en) | 1998-10-15 | 2001-09-04 | Fluoroprobe, Inc. | Method for viewing tumor tissue located within a body cavity |
CA2349333A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
EP1140204A2 (de) | 1998-12-18 | 2001-10-10 | Du Pont Pharmaceuticals Company | Vitronektin-rezeptor antagonist arzeimittheln |
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
DE19924138A1 (de) | 1999-05-26 | 2000-11-30 | Henkel Kgaa | Lösbare Klebeverbindungen |
GB9922173D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
JP2003531105A (ja) * | 1999-10-15 | 2003-10-21 | メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ | 造影剤および治療薬として有用なコバラミン結合体 |
DE19951599A1 (de) * | 1999-10-27 | 2001-05-23 | Henkel Kgaa | Verfahren zur adhesiven Trennung von Klebeverbunden |
EP1267935A2 (de) * | 2000-01-12 | 2003-01-02 | Light Sciences Corporation | Behandlung von augenerkrankungen |
US6989139B2 (en) | 2000-02-15 | 2006-01-24 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
US6656448B1 (en) * | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
KR100866666B1 (ko) * | 2000-04-12 | 2008-11-04 | 지이 헬스케어 에이에스 | 펩티드 기재 화합물 |
CA2410906C (en) | 2000-06-02 | 2012-10-02 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (ec)-drug conjugates |
US8263739B2 (en) | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
EP2279757A3 (de) * | 2000-06-02 | 2011-08-03 | Bracco Suisse SA | Arzneimitteln zum Targeting von Endothelzellen |
AU7002501A (en) * | 2000-06-21 | 2002-01-02 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
DE10037884A1 (de) * | 2000-08-03 | 2002-02-21 | Henkel Kgaa | Verfahren zur beschleunigten Klebstoffaushärtung |
NO20004795D0 (no) | 2000-09-26 | 2000-09-26 | Nycomed Imaging As | Peptidbaserte forbindelser |
BRPI0210886B8 (pt) | 2001-07-10 | 2021-05-25 | Amersham Health As | composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal |
US7087212B2 (en) * | 2001-08-17 | 2006-08-08 | Mallinckrodt, Inc | Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
US20030100830A1 (en) * | 2001-11-27 | 2003-05-29 | Sheng-Ping Zhong | Implantable or insertable medical devices visible under magnetic resonance imaging |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US20050250700A1 (en) * | 2002-03-01 | 2005-11-10 | Sato Aaron K | KDR and VEGF/KDR binding peptides |
US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
EP1587944A4 (de) * | 2002-03-01 | 2007-03-21 | Dyax Corp | Kdr und vegf/kdr-bindende peptide und ihre diagnostische und therapeutische veranwendung bei der diagnose und therapie |
US7985402B2 (en) * | 2002-03-01 | 2011-07-26 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
US7666979B2 (en) | 2002-03-01 | 2010-02-23 | Bracco International B.V. | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same |
EP1369134A1 (de) * | 2002-06-05 | 2003-12-10 | Bracco Imaging S.p.A. | Mittel fur magnetisches Bildformungsverfahren |
JP2004138397A (ja) * | 2002-10-15 | 2004-05-13 | Kyowa Hakko Kogyo Co Ltd | 特定部位に集積する化合物のスクリーニング方法 |
SI2949658T1 (sl) | 2003-03-03 | 2018-10-30 | Dyax Corp. | Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe |
FR2856689A1 (fr) * | 2003-06-25 | 2004-12-31 | Guerbet Sa | Composes specifiques a forte relaxivite |
US20060239913A1 (en) * | 2003-06-25 | 2006-10-26 | Marc Port | Peptide conjugate for magnetic resonance imaging |
NO20034350D0 (no) * | 2003-09-29 | 2003-09-29 | Amersham Health As | Optisk avbilding av kolorektal kreft |
US7431915B2 (en) | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
US9695251B2 (en) | 2003-10-31 | 2017-07-04 | The Regents Of The University Of California | Activatable cell penetrating peptides with quenched fluorophores |
US7985401B2 (en) * | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
US9050378B2 (en) * | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
NO20035683D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av prostatakreft |
NO20035681D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av lungekreft |
NO20035682D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av ösofagkreft og Barretts ösofag |
NO20035748D0 (no) * | 2003-12-19 | 2003-12-19 | Amersham Health As | Optisk avbildning av sårbar arteriosklerose |
US20070098631A2 (en) * | 2004-04-28 | 2007-05-03 | Guerbet | Diagnostic compounds comprising a scaffold coupled to a signal entity for medical imaging diagnostic |
US7553810B2 (en) * | 2004-06-16 | 2009-06-30 | Pneumrx, Inc. | Lung volume reduction using glue composition |
US7678767B2 (en) | 2004-06-16 | 2010-03-16 | Pneumrx, Inc. | Glue compositions for lung volume reduction |
US20050281798A1 (en) * | 2004-06-16 | 2005-12-22 | Glen Gong | Targeting sites of damaged lung tissue using composition |
US20050281740A1 (en) * | 2004-06-16 | 2005-12-22 | Glen Gong | Imaging damaged lung tissue |
US7608579B2 (en) * | 2004-06-16 | 2009-10-27 | Pneumrx, Inc. | Lung volume reduction using glue compositions |
US20050281799A1 (en) * | 2004-06-16 | 2005-12-22 | Glen Gong | Targeting damaged lung tissue using compositions |
US20050281739A1 (en) * | 2004-06-16 | 2005-12-22 | Glen Gong | Imaging damaged lung tissue using compositions |
US7766938B2 (en) * | 2004-07-08 | 2010-08-03 | Pneumrx, Inc. | Pleural effusion treatment device, method and material |
EP1619501B1 (de) * | 2004-07-22 | 2007-09-26 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind |
GB0421308D0 (en) * | 2004-09-24 | 2004-10-27 | Amersham Plc | Enzyme inhibitor imaging agents |
WO2006107794A2 (en) * | 2005-04-01 | 2006-10-12 | The Board Of Regents Of The University Of Texas System | Poly(peptide) as a chelator: methods of manufacture and uses |
US8349991B2 (en) * | 2005-04-19 | 2013-01-08 | Massachusetts Institute Of Technology | Amphiphilic polymers and methods of use thereof |
WO2007030012A2 (en) * | 2005-09-05 | 2007-03-15 | Stichting Voor De Technische Wetenscahappen | Extracellular matrix imaging |
US20070140974A1 (en) * | 2005-12-15 | 2007-06-21 | General Electric Company | Targeted nanoparticles for magnetic resonance imaging |
EP2510943B1 (de) | 2006-02-06 | 2016-04-20 | The Burnham Institute for Medical Research | Verfahren und Zusammensetzungen in Verbindung mit Targeting von Tumoren und Wunden |
US8758723B2 (en) * | 2006-04-19 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
WO2008036763A2 (en) * | 2006-09-20 | 2008-03-27 | Pneumrx, Inc. | Tissue adhesive compositions and methods thereof |
US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
WO2008136869A2 (en) | 2006-12-06 | 2008-11-13 | Burnham Institute For Medical Research | Methods and compositions related to targeting wounds, regenerating tissue, and tumors |
US9101671B2 (en) | 2007-01-03 | 2015-08-11 | Sanford-Burnham Medical Research Institute | Methods and compositions related to clot binding compounds |
DE102007036570A1 (de) * | 2007-08-03 | 2009-02-19 | Siemens Ag | Screeningtest zur Erkennung von Prostataerkrankungen sowie Vorrichtung und Diagnosesubstanz zur Durchführung des Tests |
DE102007037008B4 (de) * | 2007-08-06 | 2015-09-10 | Siemens Aktiengesellschaft | Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors |
DE102007041836A1 (de) * | 2007-09-03 | 2009-03-05 | Siemens Ag | Verfahren zur Abbildung eines Prostatatumors und dafür geeignetes Kontrastmittel |
US20090074672A1 (en) * | 2007-09-17 | 2009-03-19 | Sri International | Tumor Boundary Imaging |
CA2699912A1 (en) | 2007-09-19 | 2009-03-26 | Oncofluor, Inc. | Method for imaging and treating organs and tissues |
US20100143258A1 (en) * | 2008-12-05 | 2010-06-10 | General Electric Company | Tumor margin imaging agents |
CN102265158A (zh) | 2008-12-23 | 2011-11-30 | 通用电气健康护理有限公司 | 99mTc肽基化合物作为骨髓成像剂的应用 |
US8753604B2 (en) * | 2008-12-23 | 2014-06-17 | Sanford-Burnham Medical Research Institute | Methods and compositions for synaphically-targeted treatment for cancer |
US11235062B2 (en) * | 2009-03-06 | 2022-02-01 | Metaqor Llc | Dynamic bio-nanoparticle elements |
US11096901B2 (en) | 2009-03-06 | 2021-08-24 | Metaqor Llc | Dynamic bio-nanoparticle platforms |
EP2454271A4 (de) * | 2009-07-15 | 2015-08-12 | Univ California | Peptide mit steuerbarer zellulärer aufnahme |
WO2011043980A1 (en) | 2009-10-07 | 2011-04-14 | Sanford Burnham Medical Research Institute | Methods and compositions related to clot-binding lipid compounds |
WO2011049964A1 (en) | 2009-10-19 | 2011-04-28 | Lab Scientific Group | Rna detection and quantitation |
US8912136B2 (en) | 2009-12-18 | 2014-12-16 | Sanford-Burnham Medical Research Institute | Methods and compositions related to clot-binding compounds |
EP2515944B1 (de) | 2009-12-23 | 2020-04-22 | Sanford-Burnham Medical Research Institute | Verfahren und zusammensetzungen im zusammenhang mit annexin 1-bindenden verbindungen |
EP2555802A1 (de) | 2010-04-08 | 2013-02-13 | Sanford-Burnham Medical Research Institute | Verfahren und zusammensetzungen zur optimierten freisetzung von verbindungen |
WO2012136813A2 (en) | 2011-04-07 | 2012-10-11 | Universitetet I Oslo | Agents for medical radar diagnosis |
US20130156803A1 (en) | 2011-06-04 | 2013-06-20 | Rochester General Hospital Research Institute | Compositions and methods related to p6 |
WO2013070688A1 (en) * | 2011-11-11 | 2013-05-16 | Yale University | Reprogramming urokinase into an antibody-recruiting anticancer agent |
US10029017B2 (en) | 2013-01-29 | 2018-07-24 | The Regents Of The University Of California | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug |
CN105102484B (zh) | 2013-01-30 | 2020-03-10 | 艾维拉斯生物科学公司 | 选择性递送分子及使用方法 |
EP3164420A4 (de) * | 2014-06-30 | 2018-05-23 | Tarveda Therapeutics, Inc. | Gerichtete konjugate sowie partikel und formulierungen davon |
DK3193945T3 (da) | 2014-09-17 | 2020-11-16 | Fluoguide As | Upar-målrettende peptid til anvendelse ved peroperativ optisk billeddannelse af invasiv cancer |
US10385380B2 (en) | 2014-10-02 | 2019-08-20 | The Regents Of The University Of California | Personalized protease assay to measure protease activity in neoplasms |
EP3037820A1 (de) * | 2014-12-27 | 2016-06-29 | Miltenyi Biotec GmbH | Zellerkennungsverfahren und Reagenzien mit lösbarem Etikettierungsteil |
US20180221513A1 (en) * | 2015-03-16 | 2018-08-09 | Northwestern University | Contrast-agent-labeled peptide amphiphile nanofibers |
US10596259B2 (en) | 2015-05-20 | 2020-03-24 | The Regents Of The University Of California | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof |
WO2017147240A1 (en) | 2016-02-23 | 2017-08-31 | Tarveda Therapeutics, Inc. | Hsp90 targeted conjugates and particles and formulations thereof |
EP3490615A4 (de) * | 2016-07-27 | 2020-04-01 | The Trustees of Columbia University in the City of New York | Gelgebundene zusammensetzungen für strahlentherapie und verwendungen davon |
EP3412303A1 (de) | 2017-06-08 | 2018-12-12 | Medizinische Universität Innsbruck | Verbessertes pharmakokinetik- und cholecystokinin-2-rezeptor (cck2r)-zielverfahren für diagnose und therapie |
WO2020198074A1 (en) | 2019-03-22 | 2020-10-01 | Reflexion Pharmaceuticals, Inc. | D-peptidic compounds for vegf |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672334A (en) * | 1991-01-16 | 1997-09-30 | Access Pharmaceuticals, Inc. | Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans |
MY106120A (en) * | 1988-12-05 | 1995-03-31 | Novartis Ag | Peptide derivatives. |
AU638043B2 (en) * | 1989-07-20 | 1993-06-17 | Novartis Ag | Labeled polypeptide derivatives |
US5183900A (en) | 1990-11-21 | 1993-02-02 | Galardy Richard E | Matrix metalloprotease inhibitors |
US6107459A (en) * | 1991-02-08 | 2000-08-22 | Diatide, Inc. | Technetium-99m labeled peptides for diagnostic imaging |
EP0627940B1 (de) | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren |
US5508020A (en) * | 1992-06-05 | 1996-04-16 | Diatech, Inc. | Technetium-99M labeled peptides for imaging |
GB9215665D0 (en) * | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
CN1173991C (zh) * | 1992-11-13 | 2004-11-03 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
US5512591A (en) * | 1993-02-18 | 1996-04-30 | President And Fellows Of Harvard College | Treatments for diseases characterized by neovascularization |
JP3670309B2 (ja) * | 1993-04-01 | 2005-07-13 | 第一製薬株式会社 | 二環性複素環化合物 |
US5480970A (en) | 1993-12-22 | 1996-01-02 | Resolution Pharmaceuticals | Metal chelators |
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
GB9502065D0 (en) * | 1995-02-02 | 1995-03-22 | Nycomed Imaging As | Contrast media |
US6027711A (en) * | 1995-06-07 | 2000-02-22 | Rhomed Incorporated | Structurally determined metallo-constructs and applications |
DE19522774A1 (de) * | 1995-06-27 | 1997-01-02 | Ifu Gmbh | Einrichtung zur spektroskopischen Untersuchung von Proben, die dem menschlichen Körper entnommen wurden |
TR199801530T2 (xx) * | 1996-02-13 | 1998-11-23 | Zeneca Limited | VEGF �nhibit�rleri olarak kinazolin t�revleri. |
NZ332234A (en) * | 1996-03-12 | 2000-06-23 | Pg Txl Company Lp | Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer |
EP0901373B1 (de) * | 1996-04-10 | 2002-11-06 | Merck & Co., Inc. | Alpha v Beta 3 ANTAGONISTEN |
EP0946202B1 (de) * | 1996-10-28 | 2003-09-10 | Amersham Health AS | Kontrastmittel |
GB9708265D0 (en) * | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
IL131655A0 (en) * | 1997-03-04 | 2001-01-28 | Bio Technology General Corp | Isolation of tissue specific ligands and their use for targeting pharmaceuticals to organs |
AU757554B2 (en) | 1998-02-11 | 2003-02-27 | Bracco International B.V. | Angiogenesis targeting molecules |
-
1997
- 1997-04-24 GB GBGB9708265.5A patent/GB9708265D0/en active Pending
-
1998
- 1998-04-24 AT AT98917461T patent/ATE270116T1/de not_active IP Right Cessation
- 1998-04-24 DE DE69837975T patent/DE69837975T2/de not_active Expired - Lifetime
- 1998-04-24 EP EP98917461A patent/EP0977600B1/de not_active Expired - Lifetime
- 1998-04-24 ES ES98917461T patent/ES2224379T3/es not_active Expired - Lifetime
- 1998-04-24 DK DK04007226T patent/DK1442751T3/da active
- 1998-04-24 ES ES04007226T patent/ES2287599T3/es not_active Expired - Lifetime
- 1998-04-24 EP EP04007226A patent/EP1442751B1/de not_active Expired - Lifetime
- 1998-04-24 JP JP54530798A patent/JP4993419B2/ja not_active Expired - Fee Related
- 1998-04-24 WO PCT/GB1998/001197 patent/WO1998047541A1/en active IP Right Grant
- 1998-04-24 DE DE69824842T patent/DE69824842T2/de not_active Expired - Lifetime
- 1998-04-24 AU AU70687/98A patent/AU7068798A/en not_active Abandoned
- 1998-04-24 AT AT04007226T patent/ATE365054T1/de not_active IP Right Cessation
-
1999
- 1999-10-22 US US09/422,977 patent/US6610269B1/en not_active Expired - Fee Related
-
2003
- 2003-06-17 US US10/462,836 patent/US7413727B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0977600A2 (de) | 2000-02-09 |
DK1442751T3 (da) | 2007-09-24 |
US7413727B2 (en) | 2008-08-19 |
DE69837975D1 (de) | 2007-08-02 |
WO1998047541A1 (en) | 1998-10-29 |
GB9708265D0 (en) | 1997-06-18 |
ES2224379T3 (es) | 2005-03-01 |
AU7068798A (en) | 1998-11-13 |
US6610269B1 (en) | 2003-08-26 |
ES2287599T3 (es) | 2007-12-16 |
DE69824842T2 (de) | 2005-11-17 |
ATE270116T1 (de) | 2004-07-15 |
EP1442751B1 (de) | 2007-06-20 |
JP2002511845A (ja) | 2002-04-16 |
ATE365054T1 (de) | 2007-07-15 |
EP0977600B1 (de) | 2004-06-30 |
JP4993419B2 (ja) | 2012-08-08 |
DE69837975T2 (de) | 2008-02-28 |
EP1442751A1 (de) | 2004-08-04 |
US20040009122A1 (en) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE270116T1 (de) | Kontrastmittel, die auf angiogenese-rezeptoren zielen | |
ATE314097T1 (de) | Kontrastmittel | |
WO1998018497A3 (en) | Contrast agents | |
IT1270882B (it) | Oligopeptidi ad attivita' fungicida | |
DE69619526T2 (de) | Fgf9 als spezifischer ligand für fgfr3 | |
DE69910216D1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
EP1120037A3 (de) | Konstruktion mit Gerät zum Melken von Tieren | |
MA26781A1 (fr) | Derives de l'acide carbamique et leur utilisation en tant que ligands recepteurs de glutamate metabotropique | |
NO20073039L (no) | Kontrastmidler | |
MX9601320A (es) | Formas de cadena unica de cuarteto de hormona de glicoproteina. | |
UY25972A1 (es) | Bencimidazoles antagonistas de angiotensina ii | |
FI961600A (fi) | Glykoproteiinihormonikvartetin yksiketjumuotoja | |
DE602004020049D1 (de) | Kontrastmittel | |
EA200000198A1 (ru) | 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов | |
DE69809944T2 (de) | Fettsäuren als eine nährungsergänzung | |
FR2668054B1 (fr) | Embout de sonde pour l'insemination artificielle d'animaux tels que des truies. | |
SE9704778D0 (sv) | An animal related apparatus | |
DE60336455D1 (de) | Kupplungsmittel, deren aktive zwischenverbindungen und konjugate sowie die verwendung dieser konjugate für diagnostische zwecke | |
EP0826578A3 (de) | Vorrichtung zum Verschieben eine Schlepperkabine relativ zu einem Schlepperaufbau | |
ATE272309T1 (de) | Gamasche zum schutz eines beines eines pferds, insbesondere zum schutz von röhrenbein und fessel von springpferden | |
FR2724308B1 (fr) | Sonde pour l'insemination artificielle d'animaux tels que des truies | |
IT1307019B1 (it) | Finimento a pettorina per cani o altri animali. | |
ES1043020U (es) | Arnes perfeccionado para perros. | |
BR7502573U (pt) | Pulverizador de barra com tra-Æo animal e mec-nica para agricultura | |
ITBO970505A0 (it) | Sistema per l'identificazione di animali. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: GE HEALTHCARE AS, OSLO, NO |
|
8328 | Change in the person/name/address of the agent |
Representative=s name: HAMMONDS LLP, LONDON, GB |
|
R082 | Change of representative |
Ref document number: 977600 Country of ref document: EP Representative=s name: J D REYNOLDS & CO., GB |